Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $63.00 Price Target at Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN) had its target price hoisted by analysts at Cantor Fitzgerald from $46.00 to $63.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 31.76% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Piper Sandler upped their price target on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a “neutral” rating in a report on Friday, August 29th. Wall Street Zen raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Finally, Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $51.50.

Supernus Pharmaceuticals Stock Up 0.5%

SUPN traded up $0.22 during trading on Tuesday, hitting $47.82. The company’s stock had a trading volume of 79,957 shares, compared to its average volume of 642,551. The firm has a market capitalization of $2.68 billion, a P/E ratio of 41.58 and a beta of 0.79. Supernus Pharmaceuticals has a twelve month low of $29.16 and a twelve month high of $48.44. The stock’s fifty day moving average price is $42.32 and its 200-day moving average price is $35.72.

Insider Transactions at Supernus Pharmaceuticals

In other news, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total value of $315,132.82. Following the sale, the director directly owned 46,307 shares of the company’s stock, valued at approximately $1,956,933.82. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jack A. Khattar sold 29,513 shares of the stock in a transaction on Tuesday, September 23rd. The stock was sold at an average price of $47.23, for a total value of $1,393,898.99. Following the completion of the sale, the chief executive officer directly owned 1,140,883 shares in the company, valued at approximately $53,883,904.09. This represents a 2.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 292,606 shares of company stock valued at $12,869,964. 8.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds have recently bought and sold shares of SUPN. Financial Management Professionals Inc. purchased a new position in shares of Supernus Pharmaceuticals in the first quarter valued at about $30,000. Versant Capital Management Inc raised its position in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,109 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $41,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $46,000. Finally, EverSource Wealth Advisors LLC bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $51,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.